Levofloxacin Ibisqus

Levofloxacin, the active ingredient in Levofloxacin Ibisqus, is a fluoroquinolone antibiotic presented as an intravenous formulation for systemic use. It is employed to treat a broad spectrum of serious bacterial infections, including respiratory, urinary, skin and soft‑tissue infections, in adult patients. It is effective against many Gram‑negative and Gram‑positive pathogens.

GNH USA supplies Levofloxacin Ibisqus as a licensed, GDP‑compliant international pharmaceutical supplier, providing high‑quality sterile intravenous products in compliance with EU regulations and serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Levofloxacin Ibisqus is a fluoroquinolone antibiotic used to treat bacterial infections in various organ systems.

Community‑Acquired Pneumonia: eradicates typical and atypical respiratory pathogens, leading to clinical recovery. Acute Bacterial Sinusitis: clears sinus infection, relieving congestion and facial pain. Uncomplicated Urinary Tract Infection: eliminates uropathogens, resolving dysuria and urinary urgency. Skin and Soft‑Tissue Infections: treats cellulitis and wound infections caused by susceptible bacteria. Severe Gram‑Negative Infections: provides coverage for resistant Gram‑negative organisms in hospitalized patients.

Levofloxacin Ibisqus may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, sometimes watery. - Headache: transient cranial discomfort. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or rupture, especially Achilles. - QT interval prolongation: cardiac rhythm disturbances. - Severe allergic reaction: anaphylaxis, rash, swelling. - Clostridioides difficile colitis: severe diarrhea due to intestinal flora disruption.

When using Levofloxacin Ibisqus, clinicians should consider several safety precautions. - Renal impairment: adjust dose or monitor renal function in patients with reduced clearance. - CNS disorders: use caution in patients with seizures or a history of convulsions. - QT prolongation risk: avoid in patients with known cardiac arrhythmias or electrolyte imbalance. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Hypersensitivity: discontinue if allergic reactions such as rash or anaphylaxis occur. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levofloxacin Ibisqus can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: reduce absorption, separate administration by at least 2 hours. - Warfarin: may increase INR, requiring closer coagulation monitoring. - Theophylline: can raise plasma levels, increasing risk of toxicity. - Cyclosporine: may enhance nephrotoxicity, necessitate dose adjustment. - NSAIDs: combined use may increase risk of CNS stimulation and seizures.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce effectiveness, advise additional non‑hormonal contraception. - Corticosteroids: increased risk of tendon rupture, monitor for musculoskeletal pain. - Diabetic agents: potential for hypoglycemia, observe blood glucose levels. - Cimetidine: may elevate levofloxacin concentrations, adjust dose if needed.